---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic impact on families"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Economic impact on families. Topics: Income loss from work missed because of attacks; Caregiver productivity costs: US patient and caregiver survey; Caregiver time off work; Caregiver time, missed work, and children's missed school: multinational caregiver survey; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Hereditary angioedema on Families

<a id="topic-2.2.1.8.3-1"></a>

### Income loss from work missed because of attacks

> “missed work because of acute attacks resulted in an income loss of $3402 annually”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver productivity costs: US patient and caregiver survey

> “For those respondents who indicated that they were either patients or caregivers or solely caregivers, the fact that they would no longer have to take time off work or could participate in the labor force, or be more productive while at work, accounted for $7630 (14.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.3-3"></a>

### Caregiver time off work

> “Caregivers, often parents of children with HAE, may also need to take time off work to care for an HAE patient.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.3-4"></a>

### Caregiver time, missed work, and children's missed school: multinational caregiver survey

> “Using web-based surveys (July 2022‒February 2023), this international study (Argentina, Brazil, Colombia, Croatia, Denmark, Germany, Hungary, Ireland, Norway, Poland, Portugal, Romania, and Sweden) assessed the humanistic and psychosocial burden of caregivers (≥ 18 years old) of pediatric (< 18 years) and adult (≥ 18 years) patients with diagnosed HAE.”
> “In total, 120 caregivers completed the surveys: 54 caregivers of pediatric patients (CoPs; mean age 40.6 years; 79.6% female) and 66 caregivers of adult patients (CoAs; mean age 42.7 years; 48.5% female).”
> “In the 4 weeks before completing the survey, caregivers of pediatric patients reported being absent from work for 2.6 ± 5.8 days (mean ± SD; median, 1.0 day), while the patients in their care missed 3.9 ± 6.2 days of school (mean ± SD; median, 2.0 days) over the same period.”
> “Caregivers reported providing care for 23.5 ± 11.8 (mean ± SD) days per month.”
> “Caregivers of pediatric patients reported that their caregiving responsibilities limited their ability to plan their own lives in different ways, notably, to work full time (33.3%), to advance in their professional careers (25.9%), to pursue their personal interests or hobbies (25.9%), their freedom to travel or go on holiday (24.1%), and to relocate to another city or country (9.3%).”
> “In the 4 weeks before the survey, caregivers (n = 33) reported missing 0.94 ± 1.39 (mean ± SD) days of work”
> “During the patient’s most recent HAE attack, help provided by the caregivers primarily included providing emotional support (72.7%), spending time with the patient (68.2%), help with administering HAE medication (51.5%), and help with household chores (48.5%).”
> “This study was sponsored by Takeda Development Center Americas, Inc.”

Source: [Watt et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12895942/)

<a id="topic-2.2.1.8.3-5"></a>

### Caregiver absenteeism by attack frequency: European patient survey

> “The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.”
> “Patient and caregiver absenteeism increased with attack severity and frequency.”
> “Specifically, the average numbers of missed days for patients were 2.2, 6.0, and 11.6 among patients with attacks less than once a month, at least once a month but less than once a week, and at least once a week, respectively (p = 0.128), and they reported that their caregivers missed 3.3, 3.6, and 10.1 days, respectively (p = 0.088).”

Source: [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/)

<a id="topic-2.2.1.8.3-6"></a>

### Caregiver assistance with injectable on-demand treatment: US and UK interviews

> “Interview participants included 25 individuals residing in either the UK (n = 8) or US (n = 17) (Table 1).”
> “Eight patients (57%) self-administered icatibant, while six (43%) required a parent or caregiver to administer, including two of the 10 adult patients (20%) and all adolescents (n = 2).”
> “The three adolescents using C1INH had their injectable on-demand treatment administered in a health care setting.”
> “Some patients and caregivers described disruptions to leisure activities (n = 15) and having to leave work or school (n = 11), and these negative impacts were reported more frequently for adolescents.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.1.8.3-7"></a>

### Caregiver health state utility during an attack: general public time trade-off valuation in England

> “Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.”
> “Qualitative interviews were undertaken to inform vignette development for the TTO study, including vignettes for abdominal, facial, hand and laryngeal attack health states, and an attack-free and caregiver state.”
> “The caregiver rating was 0.762 (SD 0.303).”

Source: [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="topic-2.2.1.8.3-8"></a>

### Caregiver tasks and burden: US caregiver survey

> “In the United States, we conducted an online survey of adults caring for an individual with HAE to better understand their experiences with the disease and identify psychosocial impacts of providing care for a patient with HAE.”
> “Thirty caregivers provided responses to the survey.”
> “Most caregivers were family members of the care recipient and many had HAE themselves.”
> “Caregivers reported participating in a number of medical-related tasks and experiencing some burdens as a result of caring for a person with HAE.”

Source: [Craig et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33980328/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
